News & analysis on the clinical development and manufacture of large molecule drugs
Clinigen: Nick Keher
By Maggie Lynch
- Last updated on
Clinigen Group appointed Nick Keher as chief financial officer to replace Martin Abell, who has resigned and will leave the business on March 31, 2019. Keher will take over the role beginning on March 19, 2019.
Keher joins Clinigen after leaving Royal Bank of Canada, where he was a managing director and head of the bank’s European Healthcare equity research team. His experience in the European healthcare space extends over eight years, at both the Royal Bank of Canada and a previous position at Investec.
He began his career as a pharmacist before joining GlaxoSmithKline where he worked within the group’s research and development and finance teams and trained as an accountant. He is both a qualified pharmacist and accountant.
“Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets. He has a deep knowledge and insight into our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team,” said Shaun Clinton, CEO of Clinigen.